Virpax Completes FDA Required Preclinical Toxicology Studies For Its Licensed Molecular Envelope Technology

Virpax Completes FDA Required Preclinical Toxicology Studies For Its Licensed Molecular Envelope Technology
image

Virpax Pharmaceuticals, Inc. VRPX, has completed FDA required preclinical toxicology studies for its licensed Molecular Envelope Technology (MET). MET enhances the delivery of Virpax’s non-addictive pain product and its epilepsy product candidate. MET is also utilized in the company’s viral barrier product candidate. These preclinical toxicology studies were performed to evaluate the safety of the MET platform and to support the IND submission of each product candidate.

The Molecular Envelope Technology was developed by Nanomerics Ltd., a UK-based nanotechnology research and development company. Nanomerics has licensed its technology to Virpax, which is utilizing the nose-to-brain MET platform to enhance drug delivery for certain of its product candidates.

“We are working with a variety of CROs and scientific and pharmaceutical industry leaders to help us evaluate the safety of the MET platform, which underpins a number of our current drug development efforts such as AnQlar which is our viral barrier product candidate. We anticipate that MET will also be a part of our plans for current and future drug development programs. We have engaged Dr. Jeffrey Murray, a leading expert in infectious diseases who spent almost 30 years of his career with the FDA, including as the deputy division director for the division of antivirals, Center for Drug Evaluation and Research. Dr. Murray has published many articles related to antivirals and served as a reviewer for the New England Journal of Medicine while at FDA. He has been a valuable contributor to us in the antiviral area in addition to clinical trial design,” stated Dr. Sheila A. Mathias, chief scientific officer for Virpax.

Benzinga’s Cannabis Capital Conference Is Back

The most successful cannabis business event in the world, the Benzinga Cannabis Capital Conference, returns to Miami for its 16th edition. This is the place where DEALS GET DONE, where money is raised, M&A starts, and companies meet investors and key partners. Join us at the Fontainebleau Miami Beach Hotel in Florida on April 11-12. Don’t miss out. Secure your tickets now. Prices will surge very soon.

Photo by Louis Reed on Unsplash

Peyman Taeidi

Leave a Reply

Your email address will not be published. Required fields are marked *